FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2984471036> ?p ?o ?g. }

• W2984471036 endingPage "1250" @default.
• W2984471036 startingPage "1239" @default.
• W2984471036 abstract "Abstract Background Anti–tumor necrosis factor–α (anti-TNF-α) treatments are increasingly used to treat pediatric Crohn’s disease, even without a prior trial of immunomodulators, but the cost-effectiveness of such treatment algorithms has not been formally examined. Drug plan decision-makers require evidence of cost-effectiveness to inform funding decisions. The objective was to assess the incremental cost-effectiveness of early intervention with anti-TNF-α treatment vs a conventional step-up strategy per steroid-free remission-week gained from public health care and societal payer perspectives over 3 years. Methods A probabilistic microsimulation model was constructed for children with newly diagnosed moderate to severe Crohn’s disease receiving anti-TNF-α treatment and concomitant treatments within the first 3 months of diagnosis compared with children receiving standard care consisting of steroids and/or immunomodulators with the possibility of anti-TNF-α treatment after 3 months of diagnosis. A North American multicenter observational study with 360 patients provided input into clinical outcomes and health care resource use. Results Early intervention with anti-TNF-α treatment was more costly, with an incremental cost of CAD$31,112 (95% confidence interval [CI], $2939–$91,715), and more effective, with 11.3 more weeks in steroid-free remission (95% CI, 10.6–11.6) compared with standard care, resulting in an incremental cost per steroid-free remission-week gained of CAD$2756 from an Ontario public health care perspective and CAD$2968 from a societal perspective. The incremental cost-effectiveness ratio was sensitive to the price of infliximab. Conclusions The results suggest that although early anti-TNF-α was not cost-effective, it was clinically beneficial. These findings, along with other randomized controlled trial evidence, may inform formulary decision-making." @default.
• W2984471036 created "2019-11-22" @default.
• W2984471036 creator A5009290511 @default.
• W2984471036 creator A5012678020 @default.
• W2984471036 creator A5033710795 @default.
• W2984471036 creator A5067402350 @default.
• W2984471036 creator A5083390736 @default.
• W2984471036 date "2019-11-15" @default.
• W2984471036 modified "2023-10-14" @default.
• W2984471036 title "Cost-effectiveness and Clinical Outcomes of Early Anti–Tumor Necrosis Factor–α Intervention in Pediatric Crohn’s Disease" @default.
• W2984471036 cites W1520422412 @default.
• W2984471036 cites W1973651333 @default.
• W2984471036 cites W1978086188 @default.
• W2984471036 cites W1979452399 @default.
• W2984471036 cites W1985149660 @default.
• W2984471036 cites W1986742850 @default.
• W2984471036 cites W1996063338 @default.
• W2984471036 cites W2035863637 @default.
• W2984471036 cites W2039812482 @default.
• W2984471036 cites W2059127937 @default.
• W2984471036 cites W2067913824 @default.
• W2984471036 cites W2068943402 @default.
• W2984471036 cites W2074204777 @default.
• W2984471036 cites W2076620119 @default.
• W2984471036 cites W2077106621 @default.
• W2984471036 cites W2083505308 @default.
• W2984471036 cites W2094992193 @default.
• W2984471036 cites W2121569640 @default.
• W2984471036 cites W2128406046 @default.
• W2984471036 cites W2135936774 @default.
• W2984471036 cites W2145436896 @default.
• W2984471036 cites W2149774158 @default.
• W2984471036 cites W2152381563 @default.
• W2984471036 cites W2164853302 @default.
• W2984471036 cites W2164937814 @default.
• W2984471036 cites W2168550903 @default.
• W2984471036 cites W2279529970 @default.
• W2984471036 cites W2318190879 @default.
• W2984471036 cites W2528277214 @default.
• W2984471036 cites W2552997830 @default.
• W2984471036 cites W2763705296 @default.
• W2984471036 cites W4213380669 @default.
• W2984471036 cites W4238775233 @default.
• W2984471036 doi "https://doi.org/10.1093/ibd/izz267" @default.
• W2984471036 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7365807" @default.
• W2984471036 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31728510" @default.
• W2984471036 hasPublicationYear "2019" @default.
• W2984471036 type Work @default.
• W2984471036 sameAs 2984471036 @default.
• W2984471036 citedByCount "8" @default.
• W2984471036 countsByYear W29844710362020 @default.
• W2984471036 countsByYear W29844710362021 @default.
• W2984471036 countsByYear W29844710362022 @default.
• W2984471036 countsByYear W29844710362023 @default.
• W2984471036 crossrefType "journal-article" @default.
• W2984471036 hasAuthorship W2984471036A5009290511 @default.
• W2984471036 hasAuthorship W2984471036A5012678020 @default.
• W2984471036 hasAuthorship W2984471036A5033710795 @default.
• W2984471036 hasAuthorship W2984471036A5067402350 @default.
• W2984471036 hasAuthorship W2984471036A5083390736 @default.
• W2984471036 hasBestOaLocation W29844710361 @default.
• W2984471036 hasConcept C112930515 @default.
• W2984471036 hasConcept C118552586 @default.
• W2984471036 hasConcept C126322002 @default.
• W2984471036 hasConcept C1862650 @default.
• W2984471036 hasConcept C187212893 @default.
• W2984471036 hasConcept C23131810 @default.
• W2984471036 hasConcept C2777138892 @default.
• W2984471036 hasConcept C2779134260 @default.
• W2984471036 hasConcept C2779280984 @default.
• W2984471036 hasConcept C2779900020 @default.
• W2984471036 hasConcept C2780132546 @default.
• W2984471036 hasConcept C2780665704 @default.
• W2984471036 hasConcept C3019080777 @default.
• W2984471036 hasConcept C515549039 @default.
• W2984471036 hasConcept C71924100 @default.
• W2984471036 hasConceptScore W2984471036C112930515 @default.
• W2984471036 hasConceptScore W2984471036C118552586 @default.
• W2984471036 hasConceptScore W2984471036C126322002 @default.
• W2984471036 hasConceptScore W2984471036C1862650 @default.
• W2984471036 hasConceptScore W2984471036C187212893 @default.
• W2984471036 hasConceptScore W2984471036C23131810 @default.
• W2984471036 hasConceptScore W2984471036C2777138892 @default.
• W2984471036 hasConceptScore W2984471036C2779134260 @default.
• W2984471036 hasConceptScore W2984471036C2779280984 @default.
• W2984471036 hasConceptScore W2984471036C2779900020 @default.
• W2984471036 hasConceptScore W2984471036C2780132546 @default.
• W2984471036 hasConceptScore W2984471036C2780665704 @default.
• W2984471036 hasConceptScore W2984471036C3019080777 @default.
• W2984471036 hasConceptScore W2984471036C515549039 @default.
• W2984471036 hasConceptScore W2984471036C71924100 @default.
• W2984471036 hasFunder F4320334506 @default.
• W2984471036 hasIssue "8" @default.
• W2984471036 hasLocation W29844710361 @default.
• W2984471036 hasLocation W29844710362 @default.
• W2984471036 hasOpenAccess W2984471036 @default.
• W2984471036 hasPrimaryLocation W29844710361 @default.
• W2984471036 hasRelatedWork W1588288904 @default.

• next